Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of manufacturing challenges, including higher doses, tighter control of impurities, greater batch consistency, and scalable processes to meet both clinical and commercial needs.
In this GEN Podcast, two experts from SK Pharmteco, a global CMO, address these challenges and lay out some best practices that guide the manufacture of lentiviral vectors with the requisite purity, robustness, and economic feasibility required for widespread clinical adoption.
Guest speakers:
Mardhani Aparajithan, Director of Manufacturing, Science and Technology, SK Pharmteco
Tatiana Nanda, PhD, CTO, Cell and Gene Therapy, SK Pharmteco
Moderator:
Kevin Davies, PhD, Editorial Director, GEN
","author_name":"Genetic Engineering & Biotechnology News (GEN)"}